GE-backed CardioDx shoots for $86m IPO
This article was originally published in Clinica
Executive Summary
Another medtech firm is looking to capitalize on the currently favorable conditions in the public markets to raise some cash. CardioDx, a portfolio company of GE Healthcare that is developing noninvasive gene expression tests to help doctors better assess and treat patients with cardiovascular diseases, is looking to raise up to $86.3m in its IPO. It did not disclose how many shares it hopes to sell or at what price. If successful, it will list on the Nasdaq under the ticker symbol CDX.